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Abstract
Bromelain, a cysteine protease found in pineapple, is known to exert protective effects against non-alcoholic fatty liver
disease (NAFLD); however, the underlying mechanism is unclear. In this study, we aimed to investigate the molecular
mechanisms underlying the beneﬁcial effects of bromelain using in vivo and in vitro models. C57BL/6 mice were fed a
high-fat diet (HFD) with or without bromelain (20 mg/kg/day) for 12 weeks. We found that treatment with bromelain
alleviated hepatic lipid accumulation accompanied by the activation of AMP-activated protein kinase (AMPK) and
autophagy ﬂux, as evidenced by the elevated levels of phosphorylated AMPK, ATG5, ATG7, LC3-II, and lysosomeassociated membrane protein 2 (LAMP2), and the decreased levels of p62 in the liver of HFD-fed mice. In human
hepatoma Huh 7 cells, bromelain prevented oleic acid (OA)-induced lipid accumulation and increased the levels of
phosphorylated AMPK, ATG5, ATG7, LC3-II, and LAMP2 but decreased the levels of p62. Inhibition of AMPK and
autophagy ﬂux by speciﬁc inhibitors or small interfering RNAs suppressed bromelain-mediated protective effect on
lipid accumulation. Moreover, inhibition of AMPK activity abolished the activation of autophagy ﬂux in OA-treated
hepatocytes. Collectively, these ﬁndings suggest a new molecular mechanism involving the AMPK-autophagy pathway
through which bromelain confers protection against the deregulation of lipid metabolism in the liver.
Keywords: AMPK, Autophagy, Bromelain, NAFLD

1. Introduction

B

romelain is a proteolytic enzyme that can be
extracted from the bark, stem, and leaves of
pineapple (Ananas comosus) [1e3]. It was ﬁrst manufactured as a pharmaceutical product in 1956 and
has been used as a clinical medication for decades
[1,2]. The clinical indications for use of bromelain
include post-surgical inﬂammation and osteoarthritis [2,3]. Apart from these indications, many
other beneﬁcial effects have been investigated,
including antimicrobial activity, anticancer activity,
and protective effect against bronchitis, sinusitis,

and thrombophlebitis [2e4]. However, the effects of
bromelain on metabolic syndrome have not been
thoroughly explored.
Metabolic syndrome is highly associated with
obesity and inﬂammation [5]. Some known metabolic syndromes are glucose intolerance, obesity,
hypertension, and dyslipidemia [5e7]. Diseases
related to metabolic syndrome include cardiovascular disease, type 2 diabetes, and non-alcoholic
fatty liver disease (NAFLD) [5,8]. Recently, the
importance of NAFLD in metabolic syndrome has
received increased attention [9e11]. NAFLD is
deﬁned as a disease in which hepatic lipids
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accumulate to over 5%e10% of the liver weight
[11]. When NAFLD worsens, it may develop into
non-alcoholic steatohepatitis (NASH). NASH may
progress to cirrhosis and hepatocellular carcinoma
[12,13].
The global prevalence of NAFLD has been
increasing over the years [14,15]. It is the most
common liver disease, with a worldwide prevalence of approximately 25% [14,15]. The rising
prevalence has led to increased research on curing
NAFLD [16,17]. Currently, there are no specialized
medications or therapies that focus on treating
NAFLD [17]. Dietary control or bariatric surgery is
mostly used to slow NAFLD progression [16,17].
Recent studies showed autophagy and AMP-activated protein kinase (AMPK) activity as potential
therapeutic targets against NAFLD [18,19]. AMPK
is a crucial regulator of lipid metabolism, and its
activation has been shown to be beneﬁcial for
treating NAFLD [17,18]. Phosphorylation at threonine-172 of AMPK has been reported to increase
AMPK activity and exert beneﬁcial effects on lipid
metabolism [18,19]. Additionally, AMPK activation
is important for the initiation of autophagy ﬂux, an
intracellular degradation system that is important
for cellular homeostasis under various stress conditions [18,19]. Many key regulators, including
autophagy-related (ATG) proteins, microtubuleassociated protein 1A/1B-light chain 3 (LC3), and
p62, are involved in this process [20e22]. It is well
established that autophagy activation is a potent
therapeutic strategy for the treatment of NAFLD
[20,21].
Our previous study revealed that bromelain has
a protective effect against NAFLD development in
mice [23]. We demonstrated that bromelain attenuates hepatic lipid accumulation in a high-fat diet
(HFD)-fed mouse model [23]. However, the molecular
mechanism
underlying
bromelainconferred protection against NAFLD is not clear. In
this study, we aimed to clarify the role of the
AMPK-autophagy signaling pathway in the
bromelain-mediated protective effect against the
deregulation of hepatic lipid metabolism and
NAFLD. We ﬁrst investigated the effect of bromelain on the activation of AMPK and autophagy ﬂux
in the liver of HFD-fed mice, and then explored
whether the AMPK-autophagy signaling pathway
is involved in the lipid-lowering effect of bromelain in hepatocytes. Our ﬁndings demonstrate that
activation of AMPK-autophagy signaling is
required for the protective effect of bromelain
against the deregulation of hepatic lipid
metabolism.

2. Materials and methods
2.1. Reagents
Bromelain, oleic acid (OA), acridine orange, the
autophagy inhibitors chloroquine (14194) and
wortmannin (10010591), and the AMPK inhibitor
compound C (11967) were purchased from Cayman
Chemical (Ann Arbor, MI, USA). Rabbit antibodies
against LC3 (4108), p62 (5114), and phospho-AMPactivated protein kinase (p-AMPK, 2535) were purchased from Cell Signaling Technology (Danvers,
MA, USA). Rabbit antibody for AMPK (A12718) was
purchased from ABclonal (Woburn, MA, USA), and
rabbit antibody for beclin-1 (sc-11427), control small
interfering RNA (siRNA), and AMPK siRNA were
obtained from Santa Cruz Biotechnology (Dallas,
TX, USA). Lipofectamine RNAiMAX transfecbtion
reagent was purchased from Thermo Fisher Scientiﬁc (Waltham, MA, USA). Rabbit antibody for
autophagy protein 5 (ATG5, NB110-53818) and
mouse antibody for lysosome-associated membrane
protein 2 (LAMP2, NBP2-22217) were purchased
from Novus Biologicals (Centennial, CO, USA).
Rabbit antibody for autophagy protein 7 (ATG7,
ab133528), DAPI (ab104139) were obtained from
Abcam (Cambridge, UK). Horse anti-rabbit IgG
antibody (H þ L), DyLight® 488 (DI-1088) was
purchased from Vector Laboratories (Burlingame,
CA, USA). Oil red O (O0625-25G) and Nile Red
(72485-100 MG) were purchased from Merck
(Darmstadt, Germany). The AMPK inhibitor,
wz4003 (S7317) was obtained from Selleck Chemicals (Houston, TX, USA). Phosphatase inhibitor
cocktail ІІ and ІІІ, eosin Y were obtained from
SigmaeAldrich (St. Louis, MO, USA). Hematoxylin
was obtained from Electron Microscopy Sciences
(Hatﬁeld, PA, USA). Mounting gel was purchased
from MUTO Pure Chemicals (Tokyo, Japan).
2.2. Animals
This study conformed to the Guide for the Care
and Use of Laboratory Animals (Institute of Laboratory Animal Resources, eighth edition, 2011), and
all animal experiments were approved by the Animal Care and Utilization Committee of National
Yang-Ming University (No. 1070314). Eight-weekold wild-type C57BL/6 male mice were randomly
divided into two groups: the vehicle (fed with PBS)
and bromelain-treated (20 mg/kg) groups. Mice in
both groups were fed with HFD (60% of calories
from fat) for 12 weeks and daily administered with
PBS or bromelain. All mice were housed in a 12h

light/12h dark cycle room where humidity was
maintained at 40e60% and temperature at 22  C.
After 12 weeks, the mice were euthanized with CO2.
The livers were isolated, weighed, and then subjected to histological analysis or stored at 80  C.
Frozen livers were homogenized, and the lysates
were subjected to Western blot analysis.
2.3. Cell culture
Human hepatoma Huh 7 cells and Huh 7.5 cells
stably expressing GFP-conjugated LC3 were
cultured in Dulbecco's modiﬁed Eagle's medium
(DMEM) supplemented with 10% (v/v) fetal bovine
serum (FBS), 100 U/mL penicillin, and 100 mg/mL
streptomycin. Cells were cultured at 37  C in a 5%
CO2 incubator.
2.4. Histology examination
Isolated livers were ﬁxed with 10% formalin,
dehydrated with ethanol, hyalinized with xylene,
and embedded in parafﬁn. Parafﬁn blocks were cut
into 8 mm sections and deparafﬁnized with xylene,
and then rehydrated from alcohol to deionized
water for further staining, including H&E and
immunoﬂuorescent staining. For H&E staining, the
sections were stained with 0.5% (w/v) hematoxylin
at 25  C for 1 min and then 0.5% (w/v) eosin Y at
25  C for 10 s. For immunoﬂuorescent staining, the
sections were incubated with primary antibody at
4  C for overnight, and then incubated with corresponding secondary antibody at 25  C for 2 h. The
sections were covered by the mounting medium
with DAPI. For oil red O staining, the cryostat sections of the livers were ﬁxed with 10% formalin,
soaked in 30% sucrose solution overnight, and
embedded in optimal cutting temperature compound. Cryostat blocks were cut into 10 mm frozen
sections and subjected to oil red O staining. The
sections were stained with oil red O (3 mg/mL) at
25  C for 10 min. After washing, the sections were
mounted by the mounting gel.
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95  C for 10 min. Proteins were separated on 8e12%
SDS-polyacrylamide gel by electrophoresis, and the
gels were transferred onto a polyvinylidene ﬂuoride
(PVDF) membrane (Pall, Port Washington, NY,
USA), blocked with 5% skim milk for 1 h at 37  C,
and then incubated with primary antibodies overnight, followed by incubation with corresponding
secondary antibodies for 2 h. The protein bands
were detected using Ultra ECL-HRP Substrate (TUECL02, Tools Biotech, Taiwan) and quantiﬁed using
ImageJ 1.8.0 (National Institutes of Health, Bethesda,
MD, USA).
2.6. Quantiﬁcation of intracellular levels of
triglycerides
The levels of cellular triglycerides were examined
by Oil Red O and Nile red staining. The ﬂuorescence intensity of Nile red staining was measured
by ﬂuorometry (Molecular Devices, Sunnyvale, CA,
USA) using excitation/emission spectra at 540/
590 nm. Photomicrographs were digitally captured
under a Leica DMIRB microscope (Leica Biosystems, Deer Park, IL, USA).
2.7. Acidic vacuoles detection
Acridine orange staining was used to detect acidic
vacuoles, as previously described [24]. Acridine orange emits red ﬂuorescence in acidic environments,
including lysosomes and autolysosomes. The ﬂuorescence intensity of acridine orange was used to
assess the formation of autophagolysosome.
2.8. Small interference RNA transfection
Huh 7 cells were seeded in 3.5 cm dishes overnight and then starved for 6 h in serum-free DMEM.
After starvation, control siRNA or AMPK siRNA
mixed with Lipofectamine RNAiMAX transfection
reagent was added to serum-free DMEM and
incubated for 24 h. DMEM was replaced with
normal DMEM (10% FBS) and transfected cells were
used for experiments.

2.5. Western blot analysis
2.9. Statistical analysis
Cells were lysed in immunoprecipitation lysis
buffer (50 mM Tris pH 7.5, 5 mM EDTA, 300 mM
NaCl, 1% Triton X-100, 1 mM phenylmethylsulfonyl
ﬂuoride, 10 mg/mL leupeptin, 10 mg/mL aprotinin
and phosphatase inhibitor cocktail ІІ and ІІІ). Aliquots of cell lysates (50 mg protein) were mixed with
5 mL of loading dye (250 mM Tris HCl pH 6.8,
500 mM dithiothreitol, 10% SDS, 50% glycerol, and
bromophenol blue). The mixture was then heated at

The results are presented as mean ± SEM from
ﬁve independent experiments. The ManneWhitney
U test was used for comparisons of data between the
two groups. For comparisons of data from more
than two groups, one-way analysis of variance
(ANOVA) followed by Dunnett's multiple comparisons or the ManneWhitney U test was performed.
SPSS software v8.0 (SPSS Inc., Chicago, IL, USA)
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was used for all statistical analyses. Differences were
considered statistically signiﬁcant at p < 0.05.

suggest that bromelain has a protective effect
against OA-induced deregulation of lipid metabolism in hepatocytes.

3. Results
3.1. Bromelain attenuates HFD-induced lipid
accumulation in the liver and increases the
activation of AMPK and autophagy
We ﬁrst examined whether the activation of
AMPK and autophagy are involved in the beneﬁcial
effects of bromelain on hepatic lipid accumulation
in HFD-fed mice. Oil red O and H&E staining
showed that daily treatment of mice with bromelain
for 12 weeks decreased lipid accumulation in the
liver compared to the vehicle group (Fig. 1A and B).
Previous ﬁndings suggest that the activation of
AMPK and autophagy exerts a protective effect
against the development of NAFLD [25e28]. Next,
we explored whether autophagy and AMPK are
involved in the lipid-lowering effect of bromelain.
Compared to vehicle treatment, daily bromelain
treatment upregulated the protein expression of
ATG5, ATG7, and LC3-II, and downregulated the
levels of p62 (Fig. 1C), all of which are standard
markers for the activation of autophagy ﬂux [22,29].
Treatment with bromelain also increased the protein expression of LAMP2, the lysosome marker in
the livers of HFD-fed mice (Fig. 1C). Additionally,
bromelain treatment increased AMPK activation, as
evidenced by the elevated AMPK phosphorylation
(Fig. 1C). Moreover, immunohistochemistry results
demonstrated that the levels of LC3 puncta were
increased and the levels of p62 were decreased in
the livers of bromelain-treated mice (Fig. 1D and E).
These results suggest that the activation of autophagy and AMPK may play crucial roles in the
beneﬁcial effects of bromelain against the development of NAFLD.
3.2. Bromelain ameliorates OA-induced lipid
accumulation in hepatocytes
We further clariﬁed the causal relationship between autophagy, AMPK, and the beneﬁcial effects
of bromelain on hepatic lipid metabolism. We used
human hepatoma Huh 7 cells as an in vitro model.
To mimic the pathology of NAFLD, treatment with
OA was used induce lipid accumulation in Huh 7
cells. Oil red O and Nile red staining showed that
the intracellular levels of lipids in Huh 7 cells were
increased in response to OA challenge (Fig. 2A and
B). Furthermore, the OA-induced increase in intracellular lipid accumulation was abolished by
bromelain treatment (Fig. 2A and B). These results

3.3. Autophagy mediates the lipid-lowering effect
of bromelain in hepatocytes
Autophagy plays an important role in orchestrating the metabolism of intracellular lipid droplets
[20,21]. We then examined the effect of bromelain
on autophagy and found that exposure of OAtreated Huh 7 cells to bromelain induced an increase in the expression of autophagy-related proteins, including ATG5, ATG7, LC3-I, LC-3-II, and
p62, in a time-dependent manner (Fig. 3A). Moreover, bromelain time-dependently increased the
protein expression of LAMP2 in OA-treated Huh 7
cells (Fig. 3A). Furthermore, treatment with
bromelain induced the formation of autophagosomes, as evidenced by the appearance of GFP-LC3
puncta 9 h after treatment (Fig. 3B). Moreover, acridine orange staining showed that bromelain
increased autophagolysosomal activity, as evidenced by the increase in the intracellular levels of
acidic vacuoles within 9 h of treatment (Fig. 3C). We
next assessed whether activation of autophagy ﬂux
is required for the beneﬁcial effect of bromelain on
OA-induced lipid accumulation in hepatocytes.
Pretreatment with chloroquine (CQ) or wortmannin
(WM), two autophagy inhibitors for blocking the
formation of autophagolysosomes, abrogated the
protective effect of bromelain on OA-induced lipid
accumulation and activation of autophagy ﬂux
(Fig. 4A and B). Collectively, these ﬁndings suggest
that activation of the autophagy pathway is required
for the beneﬁcial effect of bromelain on OA-induced
degradation of lipids in hepatocytes.
3.4. AMPK phosphorylation is required for
bromelain-induced activation of autophagy ﬂux
AMPK is a crucial regulator of autophagy and
lipid metabolism [27,28]. Phosphorylation of AMPK
at Thr-172 promotes autophagy activation [26,27].
Therefore, we explored the role of AMPK in
bromelain-mediated activation of autophagy and
protective effect on lipid accumulation. Huh 7 cells
were treated with bromelain (2 mg/mL) for up to
240 min. We found that bromelain induced the
phosphorylation of AMPK in a time-dependent
manner at Thr-172; phosphorylation increased as
early as 15 min after treatment and peaked at
240 min (Fig. 5A). Inhibition of AMPK activation by
the pharmacological inhibitors compound C (C.C.)
and WZ4003 (WZ) abolished the protective effect of
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Fig. 1. Bromelain attenuates hepatic lipid levels, and activates AMP-activated protein kinase (AMPK) activity and autophagy in HFD-fed
mice. HFD-fed C57BL/6 mice were administered with vehicle (PBS) or bromelain (20 mg/kg/day) for 12 weeks. Representative images of (A) oil red O
staining and (B) H&E staining. (C) Western blotting analysis of p-AMPK, AMPK, ATG-5, ATG-7, LC3-I/II, p62, LAMP2 and b-actin. (D and E)
Immunoﬂuorescent staining for LC3 and p62. Data are represented as mean ± SEM from ﬁve mice. *p < 0.05 vs. vehicle group.

bromelain on the accumulation of intracellular
lipids (Fig. 5B and C). Moreover, pretreatment with
C.C. or WZ prevented the effect of bromelain on the
activation of autophagy ﬂux (Fig. 5D). To further
conﬁrm the role of AMPK activity in bromelaininduced protection against the deregulation of lipid
metabolism and activation of autophagy in hepatocytes, we used siRNA targeting AMPK expression.
Our results demonstrated that knockdown of AMPK
abrogated the beneﬁcial effects of bromelain on OAinduced lipid accumulation and activation of

autophagy ﬂux (Fig. 6A-C). Collectively, these ﬁndings strongly suggest that the AMPK-autophagy
pathway is required for the beneﬁcial effects of
bromelain on the deregulation of lipid metabolism
in hepatocytes.

4. Discussion
The anti-inﬂammatory and anti-coagulation effects of bromelain have been well-documented
[1e4]. However, much remains to be learned about
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Fig. 2. Bromelain prevents intracellular lipid accumulation in oleic acid (OA)-treated Huh 7 cells. Huh 7 cells were pretreated with OA (125 mg/mL)
for 18 h and then with or without bromelain (2 mg/mL) for an additional 18 h. (A) Representative images of oil red O staining and the relative intracellular
levels of triglycerides. (B) Representative images and the quantitation of the intensity of Nile red staining. Data are the mean ± SEM from ﬁve independent
experiments. *p < 0.05 vs. vehicle-treated group; #p < 0.05 vs. OA-treated group.

the effects and molecular mechanisms of bromelain
on metabolic diseases. In this study, we provide new
evidence for the beneﬁcial effects of bromelain on
excess fatty acid-induced lipid accumulation and
the underlying molecular mechanisms. We used a
HFD-fed mouse model and an OA-induced lipid
accumulation cell model to investigate the molecular mechanism underlying the beneﬁcial effect of
bromelain on the deregulation of lipid metabolism
in hepatocytes. We found that daily treatment with
bromelain for 12 weeks alleviated the HFD-induced
lipid accumulation in the liver. Bromelain also
induced the activation of AMPK and autophagy

ﬂux. Additionally, an in vitro study further
conﬁrmed the causal relationship between these
key events in that bromelain prevented OA-induced
lipid accumulation by activating the AMPK-autophagy signaling pathway. The observations of our
study suggest that bromelain elicits the activation of
AMPK, which in turn initiates the process of autophagy ﬂux and promotes the hydrolysis of lipid
droplets, leading to a reduction in intracellular lipid
accumulation. Although the role of autophagy in
anti-cancer action of bromelain has been reported
[3]; the role of autophagy in bromelain-conferred
protection from the deregulation of hepatic lipid
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Fig. 3. Bromelain induces activation of autophagy ﬂux in hepatocytes. Huh 7 cells were pretreated with oleic acid (OA) (125 mg/mL) for 18 h and
then with bromelain (2 mg/mL) for the indicated times. (A) Western blotting analysis of autophagy-related proteins, LAMP2 and b-actin. (B)
Representative images and quantitation of the intensity of GFP-LC3 puncta in Huh 7.5 cells. (C) Representative images of acidic vacuoles (red
ﬂuorescence) and quantitation of the intensity of acridine orange staining. Data are the mean ± SEM from ﬁve independent experiments. A, *p < 0.05
vs. vehicle group; B, *p < 0.05 vs. time zero group; C, *p < 0.05 vs. OA-treated group.

metabolism is still unclear. Our study is the ﬁrst to
demonstrate that bromelain alleviates the excess
fatty acid-induced lipid accumulation in hepatocytes and NAFLD by activating AMPK-autophagy
pathway. Collectively, these ﬁndings clarify the
molecular mechanisms underlying the protective
effects of bromelain on the deregulation of hepatic
lipid metabolism.

Regarding with the concentration of bromelain
used in this study, we have previously reported that
treatment with bromelain (20 mg/kg) for 12 weeks
effectively attenuate the progression of non-alcoholic fatty liver disease (NAFLD) in C57BL/6 mice
[23]. Therefore, we simply adopted this dosage and
tried to address the role of AMPK-autophagy
pathway in bromelain-conferred protection from

Fig. 4. Inhibition of autophagy abolishes the protective effect of bromelain on intracellular lipid accumulation in hepatocytes. Huh 7 cells
were pretreated with oleic acid (OA) (125 mg/mL) for 18 h and then chloroquine (CQ, 40 mM) and wortmannin (WM, 1 mM) for 2 h, followed by
bromelain (BL) (2 mg/mL) for an additional 18 h. (A) Representative images and quantitation of the intensity of Nile red staining. (B) Western blotting
analysis of LC3-I/II, p62, and b-actin. Data are the mean ± SEM from ﬁve independent experiments. A, *p < 0.05 vs. vehicle group, #p < 0.05 vs. OAtreated group, $p < 0.05 vs. OA þ BL-treated group; B, *p < 0.05 vs. BL-0 h group, #p < 0.05 vs. BL-9h group.
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Fig. 5. AMP-activated protein kinase (AMPK) activation is required for the bromelain-mediated beneﬁcial effect on lipid accumulation and
autophagy induction in hepatocytes. (A) Huh 7 cells were treated with bromelain (2 mg/mL) for the indicated times. Western blot analysis of
phosphorylated AMPK (p-AMPK) and AMPK. (B and C) Huh 7 cells were pretreated with oleic acid (OA) (125 mg/mL) for 18 h and then with the
AMPK inhibitor compound C (CC, 10 mM) or WZ4003 (WZ, 5 mM) for 2 h, followed by bromelain (BL) (2 mg/mL) treatment for an additional 18 h.
Representative images and quantitation of the intensity of Nile red staining. (D) Western blotting analysis of LC3-I/II, p62, and b-actin. Data are the
mean ± SEM from ﬁve independent experiments. A and D, *p < 0.05 vs. time zero group; C, *p < 0.05 vs. vehicle group, #p < 0.05 vs. OA-treated
group, $p < 0.05 vs. OA þ BL-treated group.

NAFLD in C57BL/6 mice. On the other hand, the
doses of bromelain used in our in vitro study were
determined by MTT assay. Huh 7 cells were treated
with various concentrations (0.5, 1, 2, 5, 10 mg/mL) of
bromelain for 18 h and then subjected to MTT assay.
The results showed that treatment with bromelain at
the concentrations of 0.5, 1 and 2 mg/mL had no
cytotoxic effects in Huh 7 cells; however, 5 and
10 mg/mL of bromelain showed a decrease in cell
viability (data not shown). Thus, we adopted the
concentration of 2 mg/mL bromelain for further in
vitro study.
Interestingly, the beneﬁcial effects of bromelain
are thought to be attributed to its proteolytic activity
[29e31]. For example, bromelain regulates the

leukocyte function by selectively modifying cell
surface molecules via the proteolytic activity [29,30]
Very recently, Sagar et al. reported that bromelain
inhibits SARS-CoV-2 infection by cleaving the spike
protein, transmembrane serine protease 2 and
angiotensin-converting enzyme 2, all of which are
key molecules for the entry of SARS-CoV-2 into host
cells [31]. Thus, we speculate that the proteolytic
activity is required for the beneﬁcial effect of
bromelain from deregulation of lipid metabolism in
hepatocytes. However, the exact target proteins on
the surface of hepatocyte to the enzymatic activity of
bromelain remain to be investigated.
Autophagy is an important self-degradative process that plays a fundamental role in maintaining

365
ORIGINAL ARTICLE

JOURNAL OF FOOD AND DRUG ANALYSIS 2022;30:357e368

Fig. 6. Knockdown of the expression of AMP-activated protein kinase (AMPK) abrogates the protective effect of bromelain on hepatic lipid
accumulation and activation of autophagy ﬂux. (A and B) Huh 7 cell were transfected with AMPK siRNA (20 nM) for 24 h and then were treated
with oleic acid (OA) (125 mg/mL) in the presence of bromelain (2 mg/mL) for an additional 18 h. Representative images and quantitation of the
intensity of Nile red staining. (C) Western blotting analysis of LC3-I/II, p62, and b-actin. Data are the mean ± SEM from ﬁve independent experiments. B, *p < 0.05 vs. vehicle group, #p < 0.05 vs. OA-treated group, $p < 0.05 vs. OA þ BL-treated group; C, *p < 0.05 vs. time zero group.

Fig. 7. Schematic representation of the mechanism of bromelain induced AMP-activated protein kinase (AMPK)-autophagy activation in
the liver. Schematic illustration of the proposed mechanism by which bromelain alleviates lipid accumulation in hepatocytes. As shown, bromelain
induces the phosphorylation of AMPK and ULK1, which initiates the activation of autophagy ﬂux and ultimately decreases hepatic lipid
accumulation.
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cellular and organismal homeostasis at critical times
in response to cellular stress [32]. Recently,
increasing evidence suggests that the autophagic
machinery also promotes lipid clearance by
breaking down intracellular lipid droplets in lysosomes [33,34]. To clarify whether bromelain can
activate autophagy to attenuate the lipid accumulation in hepatocytes, we analyzed the protein levels
of LC3-II and p62, indicators of the activation of
autophagy ﬂux [35,36], in the liver of mice. Our results demonstrated that bromelain could decrease
lipid accumulation in the liver by activating autophagy ﬂux. Furthermore, our in vitro study supports
the notion that treatment with bromelain activates
autophagy, as evidenced by increased ATG5, ATG7,
LC3-I, LC3-II, autophagy puncta, and lysosomal
activity, and decreased p62 and lipid accumulation
in Huh 7 cells, suggesting that bromelain promotes
the formation of autophagosomes and autophagolysosomes, and leads to the degradation of lipid
droplets in the lysosomes of hepatocytes. Moreover,
inhibition of autophagy by the pharmacological inhibitors CQ and WM [37e40] abrogated the protective effect of bromelain on lipid accumulation in
Huh 7 cells, suggesting the essential role of autophagy in bromelain-conferred protection from
deregulation of lipid metabolism. These observations revealed the potential molecular mechanisms
underlying bromelain-mediated protection from
deregulation of hepatic lipid metabolism by excess
fatty acids. However, the molecular mechanism by
which bromelain activates autophagy ﬂux in hepatocytes is not understood.
Importantly, AMPK is a key sensor of energy homeostasis in mammalian cells, [18,41]. AMPK can be
activated by an increase in the ratio of AMP to ATP
and phosphorylate downstream substrate proteins to
inhibit energy-consuming biosynthetic and ATP
catabolic pathways [19]. Notably, the physiological
role of AMPK in the regulation of lipid metabolism
has been extensively investigated [41,42]. Clinical
therapeutic agents for metabolic syndrome and lipid
metabolism-related disorders, such as metformin
and statins, exert protective effects against metabolic
diseases via the AMPK signaling pathway [42,43].
Moreover, emerging evidence indicates that AMPK
signaling is involved in the activation of autophagy
ﬂux [26,27]. Our results further conﬁrmed this notion;
inhibition of AMPK by C.C. and WZ diminished
bromelain-induced autophagy activation and lipid
clearance, suggesting that AMPK is an upstream
regulator of the activation of autophagy ﬂux by
bromelain. Furthermore, previous studies have reported that AMPK directly activates unc-51 like
autophagy activating kinase 1 (ULK1) by inducing

phosphorylation at Ser-317, which consequently initiates the activation of autophagy process [44,45].
Additionally, phosphorylated ULK1 (p-ULK1 at Ser317) activates the class III PI 3-kinase (VPS34) complex to activate autophagy [46]. Interestingly, our data
revealed that ULK1 phosphorylation at Ser-317 is also
required for bromelain-mediated activation of autophagy and lipid clearance (Fig. S1A). This ﬁnding also
suggests that ULK1 phosphorylation at Ser-317 is
important for the protective effect of bromelain on the
deregulation of lipid metabolism. However, the
causal relationship between AMPK and ULK1 in
bromelain that conferred protection against hepatic
lipid metabolism requires further investigation.
Collectively, these ﬁndings provide new insights into
the role of the AMPK-autophagy pathway in
bromelain-mediated hepatic lipid clearance under
pathological conditions.
Despite the unique pathway discovered in this
study, the detailed mechanisms by which bromelain
regulates hepatic lipid metabolism merits further
study. Overall, our results further support the notion
that activation of AMPK-autophagy signaling is
crucial in regulating lipid metabolism, which again
demonstrates the beneﬁcial effect of bromelain on
lipid metabolism. In conclusion, our in vivo and in
vitro ﬁndings suggest that activation of the AMPKautophagy signaling pathway is essential for the
bromelain-conferred protection from deregulation of
hepatic lipid metabolism and the development of
NAFLD (Fig. 7). Our ﬁndings reveal a new molecular
mechanism underlying the beneﬁcial effects of
bromelain on the pathogenesis of NAFLD, which
provides supporting evidence for a link between
bromelain and the AMPK-autophagy component in
the liver. These ﬁndings are essential for a better
understanding of the molecular mechanism of
bromelain and for identifying new therapeutic targets for treating NAFLD and related lipid disorders.

Conﬂict of interest
The authors declare no conﬂict of interest.

Author contributions
Conceptualization: Hu PA, Kou YR, Lee TS;
methodology: Hu PA, Hsu MC, Chen SH, Chen CH;
formal analysis: Hu PA; investigation: Hu PA, Hsu
MC, Chen SH; data curation: Hu PA and Lee TS;
writingdoriginal draft preparation: Hu PA, Kou YR
and Lee TS; supervision: Huang JW and Lee TS;
funding acquisition: Huang JW and Lee TS. All
authors have read and approved the published
version of the manuscript.

Data availability
The data supporting the ﬁndings of this study are
available from the corresponding author upon
reasonable request.

Acknowledgements
This study was supported by grants from the
Ministry of Science and Technology of Taiwan (1082811-B-002-542, 108-2320-B-002-032-MY3 and 1102314-B-002-269). We thank the staff of the imaging
core at the First Core Labs, National Taiwan University College of Medicine, for their technical
assistance. This article was subsidized for English
editing by National Taiwan University under the
Excellence Improvement Program for Doctoral
Students (grant number 108-2926-I-002-002-MY4),
sponsored by Ministry of Science and Technology,
Taiwan.

Appendix.

367

References
[1] Taussig SJ, Batkin S. Bromelain, the enzyme complex of
pineapple (Ananas comosus) and its clinical application. An
update. J Ethnopharmacol 1988;22(2):191e203.
[2] Pavan R, Jain S, Shraddha Kumar A. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int
2012;2012:976203.
[3] Chang TC, Wei PL, Makondi PT, Chen WT, Huang CY,
Chang YJ. Bromelain inhibits the ability of colorectal cancer
cells to proliferate via activation of ROS production and
autophagy. PLoS One 2019;14(1):e0210274.
[4] Hikisz P, Bernasinska-Slomczewska J. Beneﬁcial properties
of bromelain. Nutrients 2021;13(12):4313.
[5] Eckel RH, Alberti KG, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2010;375(9710):181e3.
[6] Huang PL. A comprehensive deﬁnition for metabolic syndrome. Dis Model Mech 2009;2(5e6):231e7.
[7] Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med 2016;26(4):364e73.
[8] Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC,
Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr
Rev 2008;29(7):777e822.
[9] Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M,
Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and
the metabolic syndrome [published correction appears in
Hepatology. 2003 Aug;38(2):536]. Hepatology 2003;37(4):
917e23.

Fig. S1. Inhibition of ULK1 eliminates bromelain-induced hepatic lipid clearance effect. Treatment with bromelain increased the p-ULK1(s-317)
to ULK1 ratio in Huh7 cells (A). Nile red staining showing that ULK1 inhibitors blocked the effect of bromelain on lipid clearance in Huh7 cells (B,
C). Results are presented by the mean ± SEM (n¼5). (A, B) *p < 0.05 vs. vehicle group. (B) #p < 0.05 vs. oleic acid (OA) group, $p < 0.05 vs. OA/
bromelain (BL) group. MR, MRT68921; SB, SBI-0206965.

ORIGINAL ARTICLE

JOURNAL OF FOOD AND DRUG ANALYSIS 2022;30:357e368

368

JOURNAL OF FOOD AND DRUG ANALYSIS 2022;30:357e368

ORIGINAL ARTICLE

[10] Targher G. Non-alcoholic fatty liver disease, the metabolic
syndrome and the risk of cardiovascular disease: the plot
thickens. Diabet Med 2007;24(1):1e6.
[11] Yki-J€
arvinen H. Non-alcoholic fatty liver disease as a cause
and a consequence of metabolic syndrome. Lancet Diabetes
Endocrinol 2014;2(11):901e10.
[12] Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and
liver cancer. Nat Rev Gastroenterol Hepatol 2013;10(11):
656e65.
[13] Ong JP, Younossi ZM. Epidemiology and natural history of
NAFLD and NASH. Clin Liver Dis 2007;11(1):1e7.
[14] Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L,
Eslam M, et al. Global burden of NAFLD and NASH: trends,
predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15(1):11e20.
[15] Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020:
the state of the disease. Gastroenterology 2020;158(7):
1851e64.
[16] Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R.
Current treatment paradigms and emerging therapies for
NAFLD/NASH. Front Biosci 2021;26:206e37.
[17] Sumida Y, Yoneda M. Current and future pharmacological
therapies for NAFLD/NASH. J Gastroenterol 2018;53(3):
362e76.
[18] Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ,
Steinberg GR. Treatment of nonalcoholic fatty liver disease:
role of AMPK. Am J Physiol Endocrinol Metab 2016;311(4):
E730e40.
[19] Herzig S, Shaw RJ. AMPK: guardian of metabolism and
mitochondrial homeostasis. Nat Rev Mol Cell Biol 2018;19(2):
121e35.
[20] Mao Y, Yu F, Wang J, Guo C, Fan X. Autophagy: a new target
for nonalcoholic fatty liver disease therapy. Hepat Med 2016;
8:27e37.
[21] Czaja MJ. Function of autophagy in nonalcoholic fatty liver
disease. Dig Dis Sci 2016;61(5):1304e13.
[22] Mizushima N. The ATG conjugation systems in autophagy.
Curr Opin Cell Biol 2020;63:1e10.
[23] Hu PA, Chen CH, Guo BC, Kou YR, Lee TS. Bromelain
confers protection against the non-alcoholic fatty liver disease in male c57bl/6 Mice. Nutrients 2020;12(5):1458.
[24] Thom
e MP, Filippi-Chiela EC, Villodre ES, Migliavaca CB,
Onzi GR, Felipe KB, et al. Ratiometric analysis of Acridine
Orange staining in the study of acidic organelles and autophagy. J Cell Sci 2016;129(24):4622e32.
[25] Mihaylova MM, Shaw RJ. The AMPK signalling pathway
coordinates cell growth, autophagy and metabolism. Nat
Cell Biol 2011;13(9):1016e23.
[26] Lu W, Mei J, Yang J, Wu Z, Liu J, Miao P, et al. ApoE deﬁciency promotes non-alcoholic fatty liver disease in mice via
impeding AMPK/mTOR mediated autophagy. Life Sci 2020;
252:117601.
[27] Alers S, L€
ofﬂer AS, Wesselborg S, Stork B. Role of AMPKmTOR-Ulk1/2 in the regulation of autophagy: cross talk,
shortcuts, and feedbacks. Mol Cell Biol 2012;32(1):2e11.
[28] Garcia D, Hellberg K, Chaix A, Wallace M, Herzig S,
Badur MG, et al. Genetic liver-speciﬁc AMPK activation
protects against diet-induced obesity and NAFLD. Cell Rep
2019;26(1):192e208. e6.

[29] Hale LP, Greer PK, Sempowski GD. Bromelain treatment
alters leukocyte expression of cell surface molecules
involved in cellular adhesion and activation. Clin Immunol
2002;104(2):183e90.
[30] Parodi A, Haddix SG, Taghipour N, Scaria S, Taraballi F,
Ceveniniet A, et al. Bromelain surface modiﬁcation increases
the diffusion of silica nanoparticles in the tumor extracellular
matrix. ACS Nano 2014;8(10):9874e83.
[31] Sagar S, Rathinavel AK, Lutz WE, Struble LR, Khurana S,
Schnaubelt AT, et al. Bromelain inhibits SARS-CoV-2
infection via targeting ACE-2, TMPRSS2, and spike protein.
Clin Transl Med 2021;11(2):e281.
[32] Rabinowitz JD, White E. Autophagy and metabolism. Science 2010;330(6009):1344e8.
[33] Dong H, Czaja MJ. Regulation of lipid droplets by autophagy. Trends Endocrinol Metabol 2011;22(6):234e40.
[34] Singh R, Cuervo AM. Lipophagy: connecting autophagy and
lipid metabolism. Int J Cell Biol 2012;2012:282041.
[35] Yoshii SR, Mizushima N. Monitoring and measuring autophagy. Int J Mol Sci 2017;18(9):1865.
[36] Zhou J, Farah BL, Sinha RA, Wu Y, Singh BK, Bay BH, et al.
Epigallocatechin-3-gallate (EGCG), a green tea polyphenol,
stimulates hepatic autophagy and lipid clearance [published
correction appears in PLoS One. 2014;9(5):e96884]. PLoS One
2014;9(1):e87161.
[37] Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ,
et al. Chloroquine inhibits autophagic ﬂux by decreasing
autophagosome-lysosome fusion. Autophagy 2018;14(8):
1435e55.
[38] Hou B, Wang G, Gao Q, Wei Y, Zhang C, Wang Y, et al.
SQSTM1/p62 loss reverses the inhibitory effect of sunitinib
on autophagy independent of AMPK signaling. Sci Rep 2019;
9(1):11087.
[39] Marchesi N, Thongon N, Pascale A, Provenzani A,
Koskela A, Korhonen E, et al. Autophagy stimulus promotes
early HuR protein activation and p62/SQSTM1 protein synthesis in ARPE-19 Cells by triggering Erk1/2, p38MAPK, and
JNK kinase pathways. Oxid Med Cell Longev 2018;2018:
4956080.
[40] Huang J, Liu K, Zhu S, Xie M, Kang R, Cao L, et al. AMPK
regulates immunometabolism in sepsis. Brain Behav Immun
2018 Aug;72:89e100.
[41] Jang M, Park R, Kim H, Namkoong S, Jo D, Huh YH, et al.
AMPK contributes to autophagosome maturation and lysosomal fusion. Sci Rep 2018;8(1):12637.
[42] Garcia D, Shaw RJ. AMPK: mechanisms of cellular energy
sensing and restoration of metabolic balance. Mol Cell 2017
Jun 15;66(6):789e800.
[43] Wu S, Zou MH. AMPK, Mitochondrial function, and cardiovascular disease. Int J Mol Sci 2020 Jul 15;21(14):4987.
[44] Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR
regulate autophagy through direct phosphorylation of Ulk1.
Nat Cell Biol 2011;13(2):132e41.
[45] Egan D, Kim J, Shaw RJ, Guan KL. The autophagy initiating
kinase ULK1 is regulated via opposing phosphorylation by
AMPK and mTOR. Autophagy 2011;7(6):643e4.
[46] Russell RC, Tian Y, Yuan H, Park HW, Chang YY, Kim J, et al.
ULK1 induces autophagy by phosphorylating Beclin-1 and
activating VPS34 lipid kinase. Nat Cell Biol 2013;15(7):741e50.

